Coxib-inhibition of Duodenal Polyp Growth in FAP

• Status: Terminated
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oslo University Hospital
• Treatments: Rofecoxib

Criteria

Inclusion Criteria:

• FAP patient with previous colectomy and confirmed polyposis

Exclusion Criteria:

• Pregnancy

• Malignancy

• NSAID hypersensitivity